ECM
CRL icon

Everence Capital Management’s Charles River Laboratories CRL Stock Holding History

Everence Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Sell
1,757
-159
-8% -$28.3K 0.02% 514
2026
Q1 		$331K Buy
1,916
+637
+50% +$118K 0.02% 526
2025
Q4 		$255K Hold
1,279
– – 0.02% 657
2025
Q3 		$200K Sell
1,279
-641
-33% -$102K 0.01% 770
2025
Q2 		$291K Hold
1,920
– – 0.02% 595
2025
Q1 		$289K Hold
1,920
– – 0.02% 580
2024
Q4 		$354K Buy
+1,920
New +$370K 0.02% 497
2024
Q3 		– Sell
-1,600
Closed -$366K – 770
2024
Q2 		$366K Hold
1,600
– – 0.03% 473
2024
Q1 		$434K Hold
1,600
– – 0.03% 454
2023
Q4 		$378K Buy
+1,600
New +$315K 0.03% 502
2022
Q4 		– Sell
-2,140
Closed -$421K – 754
2022
Q3 		$421K Hold
2,140
– – 0.04% 397
2022
Q2 		$458K Hold
2,140
– – 0.04% 372
2022
Q1 		$608K Hold
2,140
– – 0.05% 324
2021
Q4 		$806K Buy
+2,140
New +$831K 0.06% 268

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Everence Capital Management's CRL Position: Q2 2026 in Review

Everence Capital Management reduced its Charles River Laboratories (CRL) stake by 8.3% in Q2 2026, selling an estimated $28.3K and leaving 1,757 shares worth $398K. The position accounts for 0.02% of the portfolio, ranked #514.

Everence Capital Management first reported a position in CRL in Q4 2021 and has held it in 14 quarters since. The position peaked at $806K in Q4 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Everence Capital Management held 1,757 shares of Charles River Laboratories worth $398K as of Q2 2026.
  • Everence Capital Management sold 159 Charles River Laboratories shares in Q2 2026, an estimated $28.3K.
  • Charles River Laboratories made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #514 holding.
  • Everence Capital Management first reported a position in Charles River Laboratories in Q4 2021 and has held it in 14 quarters since.
  • Everence Capital Management's Charles River Laboratories position peaked at $806K in Q4 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.